3IJ0 Stock Overview
DRI Healthcare Trust focuses on managing and growing a portfolio of pharmaceutical royalties.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 2/6 |
DRI Healthcare Trust Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$10.86 |
| 52 Week High | CA$11.51 |
| 52 Week Low | CA$5.77 |
| Beta | 0.92 |
| 1 Month Change | -0.037% |
| 3 Month Change | 16.64% |
| 1 Year Change | 82.68% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 170.18% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3IJ0 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -3.0% | 1.9% | 1.2% |
| 1Y | 82.7% | -28.2% | 2.0% |
Return vs Industry: 3IJ0 exceeded the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: 3IJ0 exceeded the German Market which returned 2% over the past year.
Price Volatility
| 3IJ0 volatility | |
|---|---|
| 3IJ0 Average Weekly Movement | 4.5% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 3IJ0 has not had significant price volatility in the past 3 months.
Volatility Over Time: 3IJ0's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | n/a | Behzad Khosrowshahi | www.dricapital.com |
DRI Healthcare Trust focuses on managing and growing a portfolio of pharmaceutical royalties. It owns a portfolio of 18 royalties derived from the sale of 14 various pharmaceutical products that focuses on eight therapeutic areas. The company was incorporated in 2020 and is headquartered in Toronto, Canada.
DRI Healthcare Trust Fundamentals Summary
| 3IJ0 fundamental statistics | |
|---|---|
| Market cap | €629.43m |
| Earnings (TTM) | €86.09m |
| Revenue (TTM) | €155.09m |
7.2x
P/E Ratio4.0x
P/S RatioIs 3IJ0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3IJ0 income statement (TTM) | |
|---|---|
| Revenue | US$166.28m |
| Cost of Revenue | US$0 |
| Gross Profit | US$166.28m |
| Other Expenses | US$73.98m |
| Earnings | US$92.30m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 06, 2024
| Earnings per share (EPS) | 1.64 |
| Gross Margin | 100.00% |
| Net Profit Margin | 55.51% |
| Debt/Equity Ratio | 42.5% |
How did 3IJ0 perform over the long term?
See historical performance and comparison